Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
8th grade Avg
|
|
New words:
aid, AIN, anal, anogenital, answer, antiviral, Aptiv, arbitration, automatically, billion, BioCryst, biopsy, Biota, cel, Center, chain, claim, Commerical, Cooperative, counterclaim, CRADA, Diego, digit, dysplasia, eleven, Ergomed, Erogmed, Europhama, evidenced, exhausted, fold, Galena, genital, Genzyme, greatly, Hewitt, histological, HPV, intraepithelial, Intramural, inventiv, iv, leave, living, maximum, men, Navy, notified, overallotment, Papilloma, passed, PCR, People, pharmanet, polymerase, precursor, prioritize, problem, promising, reaction, region, remeasured, reseach, Respiratory, resupply, retroactive, reverse, San, Sanofi, sci, sexually, Shipment, shortly, situ, straight, sublease, subleased, subleasing, suppressed, takeover, Targacept, team, tissue, transmitted, unchanged, underwritten, uniformly, variation, visual, women, XOMA
Removed:
Acquiring, ARCA, aseptic, aseptically, Chelsea, clarification, codification, commercialization, consolidation, court, developer, District, elevated, EPS, equally, EU, excluding, exercising, expiring, extinguishment, fastest, formulate, heat, hold, humidity, initiation, inspect, intercompany, ISO, lab, label, landlord, lose, lowered, mimic, NeurogesX, obligation, operated, Orexigen, paragraph, potency, purity, quickly, recently, recur, refer, revalued, reverted, room, SCOLR, sensitive, Southern, stem, step, stored, Subtopic, temperature, temporarily, unmet, upcoming, VTI, yield, York
Filing tables
Filing exhibits
CVM similar filings
Filing view
External links
Exhibit 32.1
In connection with the Annual Report of CEL-SCI Corporation (the “Company”) on Form 10-K for the period ending September 30, 2013 as filed with the Securities and Exchange Commission (the “Report”), Geert Kersten, the Chief Executive and Principal Financial Officer of the Company, certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:
| (1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
| (2) | The information contained in the Report fairly presents, in all material respects the financial condition and results of the Company. |
December 27, 2013 | By: | /s/ Geert Kersten | |
| Geert Kersten, Chief Executive and Principal | |||
| Financial and Accounting Officer | |||